Delirium, Dementia, Amnestic, Cognitive Disorders  >>  atabecestat (JNJ-54861911)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
atabecestat (JNJ-54861911) / J&J
NCT02260674 / 2014-002159-24: A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease

Completed
2a
114
Europe
JNJ-54861911, 10 milligram (mg), JNJ-54861911, 50 mg, Placebo
Janssen Research & Development, LLC
Alzheimer's Disease
06/16
06/16

Download Options